Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 585 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Withdrawal Clear all
Recruiting Phase 3 Interventional

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

NCT07398417
View directory record Official record
Conditions
Fibromyalgia
Interventions
AXS-14 (Esreboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Little Rock, Arkansas • Santa Ana, California • Cromwell, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

NCT02391571
View directory record Official record
Conditions
Withdrawal Symptoms
Interventions
Oxycodone/Naltrexone Capsules, Oxycodone, Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings

NCT00974402
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Stress Disorders, Combat Disorders
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Heart Obesity Prevention Education

NCT02092545
View directory record Official record
Conditions
Obesity
Interventions
Ketogenic diet
Other
Lead sponsor
Tampa General Hospital
Other
Eligibility
25 Years to 64 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Jul 21, 2026, 5:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ph1 Marinol Interaction Study - Part 1 - 1

NCT00438139
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Dronabinol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy

NCT03077893
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Active Provant Therapy System, Inactive (sham) Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

NCT05848700
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

NCT04003207
View directory record Official record
Conditions
Phelan McDermid Syndrome
Interventions
Recombinant human Growth hormone
Drug
Lead sponsor
Swathi Sethuram
Other
Eligibility
2 Years to 12 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Jul 21, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2012 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ph1 Marinol Interaction Study - Part 2 - 1

NCT00490269
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Placebo, Dronabinol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 21, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205
View directory record Official record
Conditions
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions
Dexmedetomidine, Placebos
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 89 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

NCT01511978
View directory record Official record
Conditions
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Interventions
Continuous 3,4-DAP, Taper 3,4-DAP to Placebo
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
7
States / cities
Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 21, 2026, 5:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.

NCT02699476
View directory record Official record
Conditions
Traumatic Brain Injury, Concussion, Mild Cognitive Disorder
Interventions
Psycho-Social Therapy, Cognitive Behavioral Computer Training, Interactive Trainer-Subject Sessions, Active Control Games
Behavioral · Device
Lead sponsor
Brain & Body Health Foundation
Other
Eligibility
25 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lakeway, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

NCT05980260
View directory record Official record
Conditions
Neonatal Opiate Withdrawal Syndrome
Interventions
Symptom-based Dosing Approach, Scheduled Opioid Taper Approach
Other
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
1 Hour to 48 Hours
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Early Phase 1 Interventional

Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal

NCT03489161
View directory record Official record
Conditions
Drug Overdose, Opioid Withdrawal, Opioid-use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Jul 21, 2026, 5:01 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

"The Evaluation of Stimulant Withdrawal"

NCT00442923
View directory record Official record
Conditions
Anxiety, Relapse, Substance Addiction
Interventions
Coreg
Drug
Lead sponsor
Aaron J. Janowsky
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters

NCT00346424
View directory record Official record
Conditions
Thrombosis, Venous Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 13, 2008 · Synced Jul 21, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Treating Alcohol Withdrawal With Oral Baclofen

NCT00597701
View directory record Official record
Conditions
Alcohol Withdrawal Delirium
Interventions
Baclofen, Placebo, Lorazepam
Drug
Lead sponsor
Essentia Health
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Jul 21, 2026, 5:01 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal

NCT01945736
View directory record Official record
Conditions
Opiate Withdrawal Syndrome
Interventions
Methadone
Drug
Lead sponsor
Kevin Watt
Other
Eligibility
91 Days to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
St. Petersburg, Florida • Kansas City, Kansas • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2018 · Synced Jul 21, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 21, 2026, 5:01 AM EDT
Terminated Phase 2 Interventional Results available

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

NCT03895437
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 21, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Results available

Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms

NCT05924945
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Bridge™ active device, Bridge™ sham device
Device
Lead sponsor
Masimo Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 21, 2026, 5:01 AM EDT